Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
  • ANTI-HLA-DQ2.5 ANTIBODY
    Publication number: 20220153847
    Abstract: The present invention provides anti-HLA-DQ2.5 antibodies. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HL A-DQ2.5 and an irrelevant peptide. Furthermore, it was found that the antibodies of the invention have inhibitory effects on T cell activation.
    Type: Application
    Filed: April 1, 2020
    Publication date: May 19, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuu Okura, Noriyuki Takahashi, Takashi Tsushima, Zulkarnain Harfuddin
  • Modified antibody constant region
    Patent number: 11332533
    Abstract: The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fc? receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: May 17, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hirotake Shiraiwa
  • CHIMERIC RECEPTOR THAT RECOGNIZES ENGINEERED SITE IN ANTIBODY
    Publication number: 20220143094
    Abstract: The present disclosure provides a pharmaceutical composition for use in combination with administration of a mutated antibody having a mutation, including substitution, deletion, addition or modification, of at least one amino acid in a CH1 region, a CH2 region, a CH3 region, a CL region, or a framework region, wherein the pharmaceutical composition comprises a cell expressing a chimeric receptor, the mutated antibody is capable of binding to the extracellular binding domain of the chimeric receptor via a moiety having the mutation, and the extracellular binding domain does not bind to an antibody free of the mutation.
    Type: Application
    Filed: April 17, 2020
    Publication date: May 12, 2022
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi University
    Inventors: Mika Sakurai, Tomoyuki Igawa, Koji Tamada, Yukimi Sakoda
  • POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
    Publication number: 20220135618
    Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
  • ANTIBODY-CONTAINING FORMULATIONS
    Publication number: 20220125921
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Application
    Filed: January 12, 2022
    Publication date: April 28, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • Cross-species anti-latent TGF-beta 1 antibodies
    Patent number: 11312767
    Abstract: The objective of the invention is to provide cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1. To obtain the anti-latent TGF-beta 1 antibodies of the invention, anti-latent-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 were screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-beta 1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonists.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: April 26, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Chugai Pharmabody Research Pte. Ltd.
    Inventors: Hideaki Shimada, Masakazu Kanamori, Xing'er Christine Koo
  • ANTIBODY HAVING ENHANCED ACTIVITY, AND METHOD FOR MODIFYING SAME
    Publication number: 20220119551
    Abstract: As a result of producing ACE910 variants in which various sites of the constant regions were modified, the inventors discovered bispecific antibodies having FVIII mimetic activity higher than that of ACE910. The inventors also identified mutation positions that elevate the FVIII mimetic activity and discovered methods for elevating the FVIII mimetic activity by using the mutations.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Yuri Teranishi
  • ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION
    Publication number: 20220112296
    Abstract: An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 14, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shu Feng, Shu Wen Samantha Ho, Hirotake Shiraiwa
  • Therapeutic agents for pancreatic cancer
    Patent number: 11285208
    Abstract: We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: March 29, 2022
    Assignees: NATIONAL CANCER CENTER, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Shuichi Mitsunaga, Atsushi Ochiai, Masafumi Ikeda
  • METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY
    Publication number: 20220089715
    Abstract: One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
    Type: Application
    Filed: October 5, 2021
    Publication date: March 24, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Atsuhiko MAEDA, Kenta HARAYA, Tatsuhiko TACHIBANA, Yuki IWAYANAGI, Yuji HORI, Genki NAKAMURA, Masaru MURAOKA
  • ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE
    Publication number: 20220089743
    Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuri Ikawa, Yuu Okura, Akihiko Mizoroki
  • Therapeutic agent for a lung disease and/or method for screening for the same
    Patent number: 11279931
    Abstract: Provided are a therapeutic and/or prophylactic agent for a lung disease and a method for screening for the therapeutic and/or prophylactic agent. Provided are a therapeutic and/or prophylactic agent for a lung disease comprising an Arid5A inhibitor as an active ingredient and a method for screening for the therapeutic and/or prophylactic agent.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: March 22, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tadamitsu Kishimoto, Kazuya Masuda
  • CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof
    Patent number: 11274151
    Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: March 15, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sotaro Naoi, Shu Feng, Tomoyuki Igawa, Shu Wen Samantha Ho
  • BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY
    Publication number: 20220073644
    Abstract: The present invention provides light chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of ACE910 (Emicizumab), novel light chains showing FVIII cofactor function-substituting activity, and heavy chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of novel light chain-containing bispecific antibodies.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Yuri Teranishi, Kazuki Kato, Hikaru Koga
  • PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII
    Publication number: 20220073645
    Abstract: The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 10, 2022
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Koichiro Yoneyama
  • Fc region variant
    Patent number: 11267868
    Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: March 8, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
  • ANTIBODY CONSTANT REGION VARIANT
    Publication number: 20220064264
    Abstract: By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Hirotake Shiraiwa
  • Anti-IL31RA antibody-containing formulations
    Patent number: 11260125
    Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: March 1, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
  • Method of modifying isoelectric point of antibody via amino acid substitution in CDR
    Patent number: 11248053
    Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 15, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
  • ANTIBODY MOLECULES
    Publication number: 20220041741
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi